Publicaciones en colaboración con investigadores/as de University of Liverpool (55)

2024

  1. Core Palliative Care Research Competencies Framework for Palliative Care Clinicians

    Journal of Palliative Medicine, Vol. 27, Núm. 4, pp. 471-480

  2. Global cross-sectional survey on neonatal pharmacologic sedation and analgesia practices and pain assessment tools: impact of the sociodemographic index (SDI)

    Pediatric Research

  3. Grading the level of evidence of neonatal pharmacotherapy: midazolam and phenobarbital as examples

    Pediatric Research, Vol. 95, Núm. 1, pp. 75-83

2023

  1. Circulating proteome for pulmonary nodule malignancy

    Journal of the National Cancer Institute, Vol. 115, Núm. 9, pp. 1060-1070

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  3. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

2022

  1. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial

    Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 2, pp. 475-485

  2. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry

    Europace, Vol. 24, Núm. 5, pp. 721-728

  3. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33

  4. Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial

    Frontiers in Gastroenterology, Vol. 1

  5. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494

  6. Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 65-122

  7. Text mining and word embedding for classification of decision making variables in breast cancer surgery

    European Journal of Surgical Oncology, Vol. 48, Núm. 7, pp. 1503-1509

  8. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

    Cancers, Vol. 14, Núm. 3

  9. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    The Lancet, Vol. 399, Núm. 10319, pp. 61-116

  10. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery

    BJS Open, Vol. 6, Núm. 1

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

    Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310

  3. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

    Journal of Hematology and Oncology

2020

  1. OBEDIS Core Variables Project: European Expert Guidelines on a Minimal Core Set of Variables to Include in Randomized, Controlled Clinical Trials of Obesity Interventions

    Obesity Facts, Vol. 13, Núm. 1, pp. 1-28